OCUGEN INC. - COMMON

Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference

23 May 2022 07:34:00 By Nasdaq GlobeNewswire

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)

23 May 2022 06:36:00 By Nasdaq GlobeNewswire

Ocugen Provides Business Update and First Quarter 2022 Financial Results

06 May 2022 06:33:00 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results

02 May 2022 07:37:00 By Nasdaq GlobeNewswire

Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

29 Apr 2022 11:36:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial

25 Apr 2022 07:33:00 By Nasdaq GlobeNewswire

Ocugen, Inc. to Present at NobleCon18

19 Apr 2022 17:32:00 By Nasdaq GlobeNewswire

Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America

18 Apr 2022 07:11:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)

12 Apr 2022 08:31:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

01 Apr 2022 07:37:00 By Nasdaq GlobeNewswire